comparemela.com

Latest Breaking News On - Solucin gmb - Page 1 : comparemela.com

ITM Isotope Technologies Munich SE: ITM Announces First Patient Treated in Second Phase III Trial, COMPOSE, with ITM-11 (n c a 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the first patient has been treated in its second pivotal phase III clinical trial, COMPOSE

Valeria fisherKostenloser wertpapierhandelBen orzelekSteffen schusterJulia hofmann susanne karlssonSolucin gmbUdoj vetterCorporate communicationsDistrict courtTrophic communicationsDeutsche bank freiburgAmerican neuroendocrine tumor societyTechnologies munichTargeted radionuclide therapeuticCancers symposiumChief executive officer

ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n c a 177Lu-edotreotide) for Treatment of Neuroendocrine Tumors at ASCO-GI

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the presentation of the study design for its phase III trial, COMPOSE (NCT04919226), at the

United statesBen orzelekValeria fisherKostenloser wertpapierhandelThorvardur ragnar halfdanarsonSteffen schusterJulia hofmann susanne karlssonUdoj vetterSolucin gmbPhilipe harrisCorporate communicationsDistrict courtTrophic communicationsDeutsche bank freiburgTechnologies munichCancers symposium

vimarsana © 2020. All Rights Reserved.